Levodopa-carbidopa intestinal gel (LCIG), marketed as Duodopa® (Europe) and Duopa® (US), is a continuous intrajejunal infusion therapy for advanced Parkinson's disease that provides stable plasma levodopa concentrations and reduces motor complications.
LCIG delivers levodopa and carbidopa directly to the duodenum via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube:
- Continuous infusion: Maintains steady-state levodopa levels
- Bypasses gastric emptying: Avoids unpredictable gastric transit
- Reduced peak-trough fluctuations: Minimizes motor complications
- Carbidopa co-delivery: Reduces peripheral dopamine side effects
- Levodopa crosses the blood-brain barrier
- Converted to dopamine in the brain
- Stimulates dopaminergic receptors in the striatum
- Provides continuous dopaminergic stimulation
LCIG is indicated for patients with advanced Parkinson's disease who:
- Have motor fluctuations (ON-OFF periods) despite optimized oral therapy
- Are not adequately controlled with oral levodopa/carbidopa
- Have severe dyskinesias that interfere with quality of life
- Are cognitively intact enough to manage the device
Good candidates:
- Age typically <75 years
- Clear response to levodopa
- Motor fluctuations despite optimized oral therapy
- Good cognitive function
- Strong caregiver support
- Ability to operate the infusion system
Contraindications:
- Severe dementia
- Active psychosis
- Uncontrolled hypertension
- Recent gastrointestinal surgery
- Inability to manage the device
- Reduction in OFF time: 4-6 hours additional ON time per day
- Decreased dyskinesia severity: Up to 50% reduction in Unified Dyskinesia Rating Scale (UDysRS) scores
- Improved ON-time quality: Better mobility and function during ON periods
- Reduced levodopa equivalent daily dose (LEDD): Often can reduce oral medication
- Sleep improvement: Better sleep continuity
- Mood improvement: Reduced depression scores in some patients
- Quality of life: Significant improvements in PDQ-39 and EQ-5D scores
- Pain reduction: Reducedlevodopa-related pain episodes
- PEG-J tube: Percutaneous endoscopic gastrojejunostomy
- Portable pump: Small, lightweight infusion device
- Cassette: Pre-filled with levodopa-carbidopa gel
- Carry bag: Discreet transport system
- Initial dose: Individualized based on previous oral levodopa dose
- Morning bolus: Typically 100-200 mg levodopa
- Continuous infusion: 40-120 mg levodopa/hour
- Dose adjustments: Based on clinical response, typically every 2-3 days
- Connect to pump each morning
- Disconnect at night (typically 10-14 hours continuous use)
- Refill cassette every 24-48 hours
- Regular tube care and maintenance
- Stoma site infection: Most common complication (10-15%)
- Tube dislocation or blockage: Requires replacement
- Peritonitis: Rare but serious
- Skin irritation: Around stoma site
- Dyskinesias: May increase initially; managed with dose adjustment
- Nausea: Usually transient
- Orthostatic hypotension: Especially early in treatment
- Psychiatric symptoms: May trigger hallucinations or psychosis
- Weight loss: Due to reduced oral intake
| Feature |
LCIG |
Deep Brain Stimulation |
Apomorphine Infusion |
| Invasiveness |
Moderate (PEG-J) |
High (surgery) |
Low (subcutaneous) |
| Reversibility |
Yes |
Limited |
Yes |
| Target |
Continuous dopaminergic stimulation |
Neuronal modulation |
Continuous dopaminergic stimulation |
| Age limit |
<75 years |
<75 years |
None specific |
| Cognitive effects |
None |
Possible |
Possible |
| Best for |
Motor fluctuations |
Motor fluctuations + tremor |
Motor fluctuations |
¶ Cost and Access
- Annual cost: Approximately $50,000-70,000 USD
- Often covered by insurance with prior authorization
- Medicare Part B covers in US
- Available in Europe, North America, Asia-Pacific